Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials

Abstract

Our objective was to review all published trials of coenzyme Q 10 for hypertension, assess overall efficacy and consistency of therapeutic action and side effect incidence. Meta-analysis was performed in 12 clinical trials (362 patients) comprising three randomized controlled trials, one crossover study and eight open label studies. In the randomized controlled trials (n ¼ 120), systolic blood pressure in the treatment group was 167.7 (95% confidence interval, CI: 163.7-171.1) mm Hg before, and 151.1 (147.1-155.1) mm Hg after treatment, a decrease of 16.6 (12.6-20.6, Po0.001) mm Hg, with no significant change in the placebo group. Diastolic blood pressure in the treatment group was 103 (101-105) mm Hg before, and 94.8 (92.8-96.8) mm Hg after treatment, a decrease of 8.2 (6.2-10.2, Po0.001) mm Hg, with no significant change in the placebo group. In the crossover study (n ¼ 18), systolic blood pressure decreased by 11 mm Hg and diastolic blood pressure by 8 mm Hg (Po0.001) with no significant change with placebo. In the open label studies (n ¼ 214), mean systolic blood pressure was 162 (158.4-165.7) mm Hg before, and 148.6 (145-152.2) mm Hg after treatment, a decrease of 13.5 (9.8-17.1, Po0.001) mm Hg. Mean diastolic blood pressure was 97.1 (95.2-99.1) mm Hg before, and 86.8 (84.9-88.8) mm Hg after treatment, a decrease of 10.3 (8.4-12.3, Po0.001) mm Hg. We conclude that coenzyme Q 10 has the potential in hypertensive patients to lower systolic blood pressure by up to 17 mm Hg and diastolic blood pressure by up to 10 mm Hg without significant side effects.

Coenzyme Q10 supplementation reverses age-related impairments in spatial learning and lowers protein oxidation

“…Treatment for conditions such as hypercholesterolemia, congestive heart failure, mitochondrial disorders, statin-induced CoQ depletion, and for enhancing exercise tolerance have used dosage similar to the low dose supplemented in the current study (Beal 1999;Rosenfeldt et al 2003Rosenfeldt et al , 2007Marcoff and Thompson 2007 ), whereas the high-CoQ dose can be related to doses used in clinical trials for the treatment of Parkinson's disease (Shults and Haas 2005) or Alzheimer's disease (trial NCT00117403), and doses up to 3,000 mg/day have been examined for short periods and determined to be void of toxic effects (Ferrante et al 2005). The highCoQ dose used in our study was beneficial for spatial learning and memory when used for a short period of time; when used lifelong, a similar dose led to significant deleterious effects (Sumien et al 2009).…”

“…Several human studies have suggested that CoQ supplementation ameliorated mitochondria-related abnormalities (Bresolin et al 1990;Morisco et al 1993;Hofman-Bang et al 1995) and age-related symptoms of heart failure and hypertension as well as neurodegenerative diseases including amyotrophic lateral sclerosis, Huntington's disease, and diabetic neuropathy (Baggio et al 1993;Beal et al 1994;Koroshetz et al 1997;Ferrante et al 2002;Rosenfeldt et al 2003Rosenfeldt et al , 2007Hyson et al 2010). Furthermore, several investigations suggest that supplementation of CoQ could have effects similar to caloric restriction or antioxidant-rich foods.…”

Hemodynamic Effects of Fenofibrate and Coenzyme Q10 in Type 2 Diabetic Subjects With Left Ventricular Diastolic Dysfunction

“…Animal experiments suggest a role for PPAR-␣ in mediating hypertension and atherosclerosis (19), but their relevance to human disease is uncertain. Metaanalyses suggest that CoQ supplementation in hypertensive patients reduces CBP by up to 10 mmHg SBP and 8 mmHg DBP (9), but its effect on ABP has not been previously examined.…”

“…CoQ supplementation could improve LVDD by increasing myocardial energy production and decreasing oxidative stress, actions complementary to fenofibrate. CoQ improves endothelial function in type 2 diabetes (8), with modest beneficial effects on BP (9) and left ventricular (LV) systolic function (10).…”

An Adaptogen Usage in Outpatient Practice to Improve Cardiovascular Adaptation to Abnormal Climatic Conditions (The Heat)

“…Гипотензивные свойства Кудесана ® ранее были подтверждены в целом ряде клинических исследова-ний [8][9][10]. В нашем исследовании снижение цифр АД сопровождалось снижением СПВ.…”